  |
LG Life Sciences launched (after being spun off from LGCI); Executive Vice President Yang Heung-joon named CEO. |
 |
Request submitted to FDA for Phase II Clinical Trial of LB80380, a hepatitis B treatment; marketing agreement for Thymitaq hepatitis treatment signed with Eximas of the US; American and European sales agreement for FACTIVE® signed with Genesoft (US). |
 |
Korean genes for discovered for liver, stomach and pancreatic cancers. |
 |
Patents for production technology related to sustained release human growth hormone perceived from 22 European countries; permission received to put FACTIVE® tablets on the Korean market. |
|
  |
Second phase of construction completed at Iksan pharmaceutical plant. |
 |
FACTIVE® quinolone antibiotics approved by US FDA. |
|
FACTIVE® given IR52 Chang Young-sil Award. |
 |
Permission to use KT Mark with FACTIVE® |
|
  |
FACTIVE® given IR52 Chang Young-sil Award of the Year for 2003 (Presidential Prize). |
|
FACTIVE® approved as a new drug in Canada. |
|
Technology for hepatitis B treatment exported to Anadys Pharmaceuticals of the US. |
 |
Environmentally-safe herbicide (flucetosulfuron) commercialized. |
 |
Request submitted for first registration of bio-generic drugs in Europe. |
|
DepoMed of the US grants exclusive license to sell its diabetes medication in Korea. |
|
Sales of FACTIVE® begun in US. |
|
Biogen Idec of the US grants exclusive license to sell its psoriasis medication in Korea. |
|
 |
Joint research begun with the Korea Research Institute of Bioscience and Biotechnology on protein chips, the next-generation in diagnostics. |
|
Comprehensive cooperative research agreement signed with Seoul Asan Hospital. |
 |
Nov. 2004: Kyorin Pharmaceutical Co. of Japan grants exclusive license to sell its urinary incontinence treatment in Korea. |
|
Development of Korea first bovine mastitis vaccine completed. |
|
Joint research of dementia treatment begun with the University of Aberdeen in Scotland. |
|
Degenerative arthritis treatment (HYRUAN Plus™) commercialized. |
|
Phase II Clinical Trial for sustained release human growth hormone given to young children begun in Europe. |
|
Technology for FACTIVE® quinolone antibiotics exported to aRigen Inc. of Japan. |
|
  |
Executive President In-chel Kim named CEO |
|
Joint marketing agreement for XILEP XL® hyperlipidemia treatment concluded with Korea Novartis. |
|
European marketing approval of human growth hormone of Valtropin™. |
|
Launch of Novamet GR for treatment of diabetes. |
|
Development and commercialization of Follitrope™, an ovulation induction treatment. |
|
Co-marketing partnership with Novartis Korea for Co-Tareg™, an anti-hypertensive treatment. |
|
Development of DPP-4 class diabetes treatment. |
|
LGLS receives 2006 Most Respected Company Award. |
|
 |
KFDA approval of sustained release-human growth hormone of Declage™. |
|
Development and commercialization of chemoprotectant of Epitrol™. |
|
LGLS exported technology to Takeda Pharmaceutical Company of Japan and concluded a contract for collaboration research. |
|
Valtropin, human growth hormone, approved by US FDA |
|
Hyruan Plus™, a treatment for osteoarthritis or degenerative arthritis, earns CE Marking |
|
LGLS and Institut Pasteur Korea made the agreement for collaboration research on cardiovascular diseases |
|
LB84451, novel drug candidate for treatment of liver fibrosis, exported to Gilead Sciences of the US |
